Clinical trial · Observational
Surgery for Locally Unresectable Pancreatic Cancer
Conversion Surgery for Locally Unresectable Pancreatic Cancer - International Multi-center Observational Trial (ROBIN= suRgery for lOcally unresectaBle pancreatIc Cancer)
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Pancreatic cancer is a severe disease often diagnosed at an advanced stage, when surgery is not possible. New chemotherapy treatments can sometimes shrink the tumor and make surgery an option. This study aims to understand if surgery after such treatments can improve survival and quality of life in selected patients treated at expert centers.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Locally Advanced Pancreatic Adenocarcinoma | Pancreatic Adenocarcinoma | CURATED_BROADER | 0.78 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Questionnaire | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- HRQoL deterioration-free survival
- timeFrame
- From enrollment to the end of study period, set at 2 years
- description
- The primary outcome is HRQoL deterioration-free survival, defined as the time from surgery until definite HRQoL score deterioration and including death from any cause as an event.
Secondary outcomes (2)
- measure
- Disease-specific survival (DSS)
- timeFrame
- 2 year from enrollment
- measure
- Recurrence-free survival (RFS)
- timeFrame
- 2 year from enrollment
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Patients older than 18 years * Patients able to give informed consent * Histologically confirmed pancreatic adenocarcinoma * LAPC stage according to NCCN10 at diagnosis (Figure 1) * Received at least 4 months of induction chemotherapy * RECIST 1.1 stable disease (SD) or partial response (PR) after induction therapy * Patient considered eligible for radical resection by local MDT Exclusion Criteria: * Informed consent withdrawal * Presence of tumor characteristics precluding surgery * Presence of patient significant comorbidities precluding surgery * Unavailable pre-induction therapy abdominal imaging * Pathological confirmation of any tumor different from PDAC
References
Publications (0)
Data not yet available